Skip to main content
. 2021 Jan 29;18(6):1474–1483. doi: 10.7150/ijms.53641

Figure 3.

Figure 3

Comparison of the main therapeutic methods (A) and comorbidities (B) between serious COVID-19 patients with initial hs-cTnI concentrations on admission > 28 pg/mL and ≤ 28 pg/mL. Four patients suffered from cardiac diseases that were not termed as coronary heart disease. Two patients had bradycardia after cardiac pacemaker surgery (1 patient with hs-cTnI > 28 pg/mL and another with hs-cTnI ≤ 28 pg/mL), one patient had heart failure (hs-cTnI > 28 pg/mL) and one patient suffered from heart valve insufficiency (hs-cTnI > 28 pg/mL). COVID-19, Coronavirus disease 2019; IVIG, Intravenous immunoglobin; NIV, Non-invasive mechanical ventilation; IV, Invasive mechanical ventilation; hs-cTnI, Hypersensitive cardiac troponin I.